On June 25, 2021, the Federal Government paused all distribution of bamlanivimab and etesevimab together and etesevimab alone (to pair with the existing supply of bamlanivimab at a facility) for use under EUA 094 (PDF) (ZIP) on a national basis until further notice. In addition, FDA recommends that health care providers nationwide use authorized alternative monoclonal antibody therapies, as described below, and not use bamlanivimab and etesevimab administered together at this time.